Journal article
Predictors and prognosis of pulmonary hypertension complicating interstitial lung disease in systemic sclerosis
K Morrisroe, D Hansen, W Stevens, L Ross, J Sahhar, GS Ngian, C Hill, L Host, J Walker, S Proudman, M Nikpour
Rheumatology | OXFORD UNIV PRESS | Published : 2025
Abstract
Objective: The objective of this study was to identify those SSc patients with concurrent pulmonary hypertension (PH) (SSc-PH patients) and interstitial lung disease (ILD) and determine their disease severity, therapeutic approach, and survival. Methods: Consecutive SSc patients enrolled in the Australian Scleroderma Cohort Study (ASCS) who were diagnosed with pulmonary hypertension (via right-heart catherization) were included in the study. Logistic regression was used to determine the associations of ILD with PH hemodynamic parameters and therapeutic approach. Kaplan–Meier survival curves were used to estimate survival rates. Results: Of 1883 SSc patients, 164 (8.7%) developed incident PH ..
View full abstractGrants
Awarded by National Health and Medical Research Council of Australia Investigator Grant
Funding Acknowledgements
This work was supported by Scleroderma Australia, Arthritis Australia, Actelion Australia, Bayer, CSL Biotherapies, GlaxoSmithKline Australia and Pfizer. K.M. holds a National Health and Medical Research Council of Australia Investigator Grant (APP1197169). L.R. holds an Arthritis Australia Australian Rheumatology Association-Victoria Fellowship. M.N. holds a National Health and Medical Research Council of Australia Investigator Grant (GTN1176538).